As the healthcare landscape has begun to rely increasingly on the use of point-of-care testing at, or close to, the patient’s bedside, it is crucial to ensure those tests are accurate and reliable, since immediate clinical decisions are based on the outcomes where even the slightest error could have profound consequences.
EMQN CIC has introduced a new EQA scheme for the Genedrive® MT-RNR1 ID Kit that tests for MT-RNR1 m.1555A>G, a genetic variant associated with increased susceptibility to aminoglycoside-induced hearing loss in neonates. The scheme includes a package of validation materials to support test implementation by laboratories, thereby speeding up their POCT device performance verification. This eliminates the need for extensive patient testing which can be difficult to achieve due to the rarity of this variant in the population.
Register your expression of interest here.
Read the article here: Enhancing point-of-care testing (POCT): EMQN CIC to introduce innovative EQA schemes for genomic POCT.
